Pensionfund Sabic lowered its position in Zoetis Inc (NYSE:ZTS) by 21.6% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 24,700 shares of the company’s stock after selling 6,800 shares during the quarter. Pensionfund Sabic’s holdings in Zoetis were worth $2,104,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently made changes to their positions in ZTS. Polen Capital Management LLC increased its holdings in Zoetis by 125.3% in the 1st quarter. Polen Capital Management LLC now owns 8,943,633 shares of the company’s stock worth $746,883,000 after acquiring an additional 4,974,081 shares during the last quarter. BlackRock Inc. increased its holdings in Zoetis by 6.7% in the 1st quarter. BlackRock Inc. now owns 41,069,741 shares of the company’s stock worth $3,429,736,000 after acquiring an additional 2,584,199 shares during the last quarter. Amundi Pioneer Asset Management Inc. increased its holdings in Zoetis by 319.9% in the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 2,768,388 shares of the company’s stock worth $231,187,000 after acquiring an additional 2,109,036 shares during the last quarter. Millennium Management LLC increased its holdings in Zoetis by 208.1% in the 4th quarter. Millennium Management LLC now owns 1,984,470 shares of the company’s stock worth $142,961,000 after acquiring an additional 1,340,378 shares during the last quarter. Finally, Royal Bank of Canada increased its holdings in Zoetis by 21.0% in the 1st quarter. Royal Bank of Canada now owns 3,192,280 shares of the company’s stock worth $266,588,000 after acquiring an additional 553,802 shares during the last quarter. 90.10% of the stock is owned by institutional investors.
In other news, insider Kristin C. Peck sold 4,877 shares of the business’s stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $83.46, for a total transaction of $407,034.42. Following the completion of the transaction, the insider now owns 42,652 shares of the company’s stock, valued at $3,559,735.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.35% of the stock is currently owned by insiders.
Zoetis traded down $0.42, reaching $84.77, during mid-day trading on Monday, MarketBeat reports. 53,746 shares of the company traded hands, compared to its average volume of 2,971,384. The company has a quick ratio of 2.83, a current ratio of 4.27 and a debt-to-equity ratio of 2.51. The firm has a market capitalization of $41.22 billion, a PE ratio of 35.27, a PEG ratio of 1.88 and a beta of 0.96. Zoetis Inc has a 52-week low of $59.50 and a 52-week high of $89.25.
Zoetis (NYSE:ZTS) last posted its earnings results on Wednesday, May 2nd. The company reported $0.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.69 by $0.06. The business had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.35 billion. Zoetis had a return on equity of 68.51% and a net margin of 17.97%. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.53 EPS. equities research analysts anticipate that Zoetis Inc will post 3.06 EPS for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 4th. Stockholders of record on Friday, July 20th will be issued a dividend of $0.126 per share. This represents a $0.50 annualized dividend and a dividend yield of 0.59%. The ex-dividend date is Thursday, July 19th. Zoetis’s payout ratio is 20.83%.
Several brokerages recently weighed in on ZTS. Hilliard Lyons lowered Zoetis to a “neutral” rating in a report on Thursday, April 19th. They noted that the move was a valuation call. Morgan Stanley lowered Zoetis from an “overweight” rating to an “equal weight” rating and set a $70.00 price objective for the company. in a report on Monday, March 19th. They noted that the move was a valuation call. Citigroup reissued a “buy” rating and issued a $98.00 price objective (up previously from $85.00) on shares of Zoetis in a report on Thursday, April 19th. BMO Capital Markets reissued a “hold” rating and issued a $80.00 price objective on shares of Zoetis in a report on Wednesday, May 16th. Finally, Cantor Fitzgerald set a $90.00 price objective on Zoetis and gave the stock a “buy” rating in a report on Tuesday, May 1st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $84.73.
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.